Apogee International

NCT ID: NCT04065997

Last Updated: 2021-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

147 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-06

Study Completion Date

2021-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Medtronic is sponsoring the Apogee International registry to further confirm safety and efficacy of the HVAD™ System when used as intended, in "real world" clinical practice and to enhance scientific understanding of the implant procedure, optimized blood pressure management, anticoagulation/ antiplatelet therapies, logfile analysis and acoustic spectrum analysis in patients receiving a Medtronic HeartWare™ HVAD™ for bridge to transplant and destination therapy indications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Apogee International is a prospective, non-interventional, post-market, multi-site registry, conducted within Medtronic's Product Surveillance Registry (PSR) Platform. Enrollment into Apogee International will be comprised of newly implanted, commercial use patients with the HeartWare Ventricular Assist Device System (HVAD System).

Sites selected to participate are expected to collect data in at least one of these five modules:

1. Logfile Download;
2. Anti-coagulation / Anti-platelet Management;
3. Blood Pressure (BP) Management;
4. Acoustic Spectrum Analysis;
5. Infection Control

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients implanted with HVAD System

Patients intended to be implanted with a HeartWare HVAD per the current (local) guidelines, are eligible for enrollment into Apogee International and must be consented for Apogee International prior to the HVAD implant.

HeartWare Ventricular Assist Device

Intervention Type DEVICE

The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HeartWare Ventricular Assist Device

The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HVAD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements;
* Enrollment into Apogee International will be comprised of newly enrolled, commercial use patients with the HeartWare HVAD System;
* Patient is consented prior to the HVAD implant procedure.

Exclusion Criteria

* Patient who is, or is expected to be inaccessible for follow-up;
* Participation is excluded by local law;
* Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound the PSR results.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Vincents Hospital

Sydney, , Australia

Site Status

Medical University of Vienna

Vienna, , Austria

Site Status

UZ Leuven - Campus Gasthuisberg

Leuven, , Belgium

Site Status

Aarhus Universitetshospital

Aarhus, , Denmark

Site Status

Helsinki University Hospital

Helsinki, , Finland

Site Status

Herz- und Diabeteszentrum NRW - Ruhr-Universität Bochum

Bad Oeynhausen, , Germany

Site Status

Schuechtermann Klinik

Bad Rothenfelde, , Germany

Site Status

Deutsches Herzzentrum Berlin

Berlin, , Germany

Site Status

Universitätsklinikum Düsseldorf

Düsseldorf, , Germany

Site Status

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Herzzentrum Leipzig GmbH

Leipzig, , Germany

Site Status

Otto von Guericke Universitat - Universitätsklinikum Magdeburg

Magdeburg, , Germany

Site Status

Eberhard Karls Universität Tübingen - Universitätsklinikum Tübingen

Tübingen, , Germany

Site Status

Azienda Ospedaliero Universitaria S. Orsola Malpighi Bologna

Bologna, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

ISMETT

Palermo, , Italy

Site Status

National Research Cardiac Surgery Center

Astana, , Kazakhstan

Site Status

Al Rassoul Al Azam Hospital - Beirut Cardiac Institute

Beirut, , Lebanon

Site Status

Leiden Universitair Medisch Centrum (LUMC)

Leiden, , Netherlands

Site Status

University Medical Center Utrecht

Utrecht, , Netherlands

Site Status

Oslo Universitetssykehus-Rikshospitalet

Oslo, , Norway

Site Status

Instytut Kardiologii

Warsaw, , Poland

Site Status

Klinicki Centar Srbije

Belgrade, , Serbia

Site Status

Hospital Universitario da Coruña

A Coruña, , Spain

Site Status

Hospital Universitari de Bellvitge

Barcelona, , Spain

Site Status

UniversitätsSpital Zürich

Zurich, , Switzerland

Site Status

Ankara City Hospital

Ankara, , Turkey (Türkiye)

Site Status

Ege Universitesi Tip Fakultesi Hastanesi

Izmir, , Turkey (Türkiye)

Site Status

Royal Brompton & Harefield NHS Foundation Trust - Harefield Hospital

Harefield, , United Kingdom

Site Status

Freeman Hospital

Newcastle, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Austria Belgium Denmark Finland Germany Italy Kazakhstan Lebanon Netherlands Norway Poland Serbia Spain Switzerland Turkey (Türkiye) United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Apogee International

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ALLEVIATE-HF-HD Study
NCT05501652 COMPLETED PHASE1
Alleviate-HF-1 Study
NCT04583527 COMPLETED PHASE1